Saxenda vs Wegovy, Ozempic, Zepbound & Mounjaro

If you're reading this, you've almost certainly been told about Saxenda and wondered whether it's the right pick. You're also probably aware that there are newer, more buzzed-about GLP-1 medications — Wegovy, Ozempic, Mounjaro, Zepbound — all of which promise larger weight loss with a weekly injection instead of a daily one. The question is less "what's the difference?" and more "is Saxenda worth it in 2026, or should I start somewhere else?"

This page is intentionally not a sales pitch for one drug. It is the clinical reality: Saxenda is the oldest GLP-1 in the weight-loss category, and in head-to-head data, the newer molecules deliver roughly twice the average weight loss with fewer injections per week. That doesn't mean Saxenda is worthless — there are people and situations where it's still the right call. It does mean you should know what else is on the table before you commit to 365 injections a year.

The full comparison matrix

Here's every major weight-loss GLP-1 on one screen. Numbers come from FDA labeling and peer-reviewed clinical trials — SCALE for Saxenda, STEP for Wegovy, SURMOUNT for Zepbound and Mounjaro, and pooled Ozempic real-world data.

Sources: FDA labeling, SCALE, SURMOUNT-1, STEP-1 clinical trials.

A few things stand out even at a glance. Saxenda and Wegovy share the same list price — around $1,349 per month — yet Wegovy delivers nearly double the average weight loss with 29 fewer injections per month. Mounjaro and Zepbound (both tirzepatide) pull ahead even further, landing in the 20–22% body-weight range in the SURMOUNT-1 trial. And virtually every newer option is now available through licensed telehealth services, which was unheard of when Saxenda was the only game in town.

Saxenda vs Wegovy

This is the closest comparison on the list, because both drugs come from Novo Nordisk, both are FDA-approved specifically for chronic weight management, and both use the exact same injection pen design. They are, structurally, siblings. The difference is what's inside the cartridge and how often you have to use it.

Weight loss: about double with Wegovy

In the SCALE trial program, people on Saxenda lost an average of 8% of their starting body weight after 56 weeks. In STEP-1, people on Wegovy lost 14.9% over 68 weeks. Same trial design, same type of population, and a different molecule at a different dose — semaglutide 2.4 mg instead of liraglutide 3.0 mg. Semaglutide has a much longer half-life (about a week), which is why it only needs to be injected once a week and why it suppresses appetite more consistently between doses.

Injection frequency: daily vs weekly

If you don't love needles, this is the deal-breaker for most people. Saxenda is 365 injections per year. Wegovy is 52. Even for people who handle the daily shot just fine, weekly dosing is usually described as "easier to forget about" — the drug just runs in the background.

Side-effect profile: very similar, but smoother on Wegovy

Both drugs cause nausea, constipation, and the other GI greatest-hits of the GLP-1 class. In practice, patients on Wegovy tend to report smoother symptoms week-to-week because their blood level doesn't peak and trough every 24 hours. Saxenda, by design, gives you a daily spike in liraglutide concentration, and that spike is also when nausea is worst.

Price: identical retail, same savings card

This is where it gets ironic. Novo Nordisk prices both at roughly $1,349 per month. Both have a savings card that can drop a commercially-insured copay to around $25/month capped at $1,200/year. Neither is typically covered by Medicare or Medicaid for weight loss. Given that you pay the same, getting more weight loss and fewer injections out of the deal is an obvious argument for Wegovy.

When Saxenda still makes sense over Wegovy

There are situations where Saxenda is actually the better pick. If you've tried semaglutide in the past and had a bad reaction, the shorter-acting liraglutide gives you the ability to wash the drug out of your system within a day or two if side effects become unmanageable. If your insurance covers Saxenda but not Wegovy — which still happens on some plans that are behind on their formulary updates — you may get a better out-of-pocket price. And if a weekly injection schedule doesn't work with your routine (which is rare but real), daily dosing can be more manageable for people who thrive on strict routines.

Saxenda vs Ozempic

This one is tricky because the two drugs aren't even approved for the same thing. Saxenda is FDA-approved for weight management. Ozempic is FDA-approved for type 2 diabetes. But Ozempic is also semaglutide, the exact same active ingredient as Wegovy, just at lower doses. So when people ask "Saxenda vs Ozempic for weight loss," what they're really asking is "should I take a weight-loss-labeled liraglutide or an off-label lower-dose semaglutide?"

The real-world answer over the last three years has been: Ozempic, mostly because of supply and cost. It's priced about 30% below Saxenda retail (~$968/month vs ~$1,349), it's weekly, and physicians were comfortable prescribing it off-label because of Ozempic's excellent diabetes data (in SUSTAIN-6, it even reduced cardiovascular events). In trials, off-label Ozempic use for obesity still produced 12–15% weight loss — well ahead of Saxenda's 8%.

The catch is that prescribing a diabetes drug for weight loss is off- label, and many insurance plans refuse to cover Ozempic for people without a diabetes diagnosis. If that's you, Wegovy or Zepbound are the on-label equivalents and often the easier path through prior authorization.

Is Saxenda the same as Ozempic?

No. Same class, different molecule. Saxenda is liraglutide, which is human GLP-1 with a fatty-acid chain added to slow its breakdown. Ozempic is semaglutide, a completely different molecule built to resist enzyme degradation for an entire week. Both activate the GLP-1 receptor. Only semaglutide stays in the body long enough to be dosed weekly.

Saxenda vs Zepbound & Mounjaro

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly. Zepbound is the FDA-approved weight-loss branding. Mounjaro is the diabetes branding. Same drug, different labels, different marketing. If we're being honest, this is the comparison where Saxenda looks the weakest.

Weight loss: 20–22% vs 8%

Tirzepatide is a dual agonist — it hits both the GLP-1 receptor AND the GIP receptor. GIP is another gut hormone with appetite and metabolism effects, and the combination appears to be synergistic. In the SURMOUNT-1 trial, patients on the top tirzepatide dose lost 22.5% of their body weight at 72 weeks. For a 220-pound person, that's about 50 pounds. Saxenda's 8% on the same person would be closer to 18.

Price: Zepbound is cheaper than Saxenda

Eli Lilly priced Zepbound around $1,059 per month at launch. That's meaningfully below Saxenda's $1,349. Lilly also launched LillyDirect self-pay, which sells Zepbound vials at roughly $349–549 per month depending on the dose. There is no equivalent direct-to-consumer program for Saxenda.

Why would anyone still pick Saxenda over Zepbound?

Honestly, only a few legitimate reasons: you have a contraindication to tirzepatide, your insurance has been slow to add Zepbound to its formulary, or you're trying to keep a shorter drug half-life in case you get pregnant (all GLP-1s are contraindicated in pregnancy, but liraglutide washes out faster). For most everyday weight-loss patients, Zepbound is the stronger drug at a lower retail price with fewer injections. It's hard to argue against that.

Saxenda vs Victoza

This one always confuses people because Saxenda and Victoza are the same drug at different doses, sold under different names, by the same company, for different conditions.

• Victoza is liraglutide 0.6–1.8 mg/day, FDA-approved for type 2 diabetes.
• Saxenda is liraglutide 0.6–3.0 mg/day, FDA-approved for weight management.

If you're on Victoza for diabetes and want to "upgrade" to Saxenda for weight loss, it's just a dose increase of the same molecule. If you're on Saxenda for weight loss and develop diabetes, your doctor may move you to Victoza (lower daily cost for diabetes coverage). Some physicians will write the script interchangeably, but insurance companies treat them as different drugs because the FDA labels them differently.

Is there a cheaper Victoza trick?

You'll see online forums suggest that using Victoza off-label for weight loss is cheaper than Saxenda. It used to be, because you'd use a smaller dose and go through fewer pens. In 2026, with Zepbound's LillyDirect self-pay and multiple telehealth semaglutide programs available under $300 per month, the Victoza workaround is no longer the cheapest path to GLP-1 weight-loss therapy.

Switching from Saxenda to a newer GLP-1

If you're already on Saxenda, switching to Wegovy, Zepbound, Ozempic, or Mounjaro is usually straightforward. The basic idea is that you stop Saxenda and start the new drug's titration schedule from the bottom. You don't keep taking both. You don't try to "bridge" one to the other.

Practical switching steps

1. Talk to a prescriber. This is not a DIY move — a provider needs to approve the switch, update your chart, and write the new script.
2. Stop Saxenda on a Sunday or Monday. Any day works, but aligning your "last shot" day with the start of the week makes tracking easier.
3. Wait 24–48 hours. Liraglutide clears the system quickly because of its short half-life (about 13 hours). Most prescribers recommend a 24–48 hour gap before the new drug.
4. Start the new drug at its lowest titration dose. Wegovy and Ozempic start at 0.25 mg per week. Zepbound and Mounjaro start at 2.5 mg per week. Do not skip the titration — it prevents a rebound of nausea.
5. Expect a week or two of adjustment. Your body is already primed from Saxenda, but the longer-acting drug will feel different — steadier appetite suppression, maybe more fatigue at first. Usually smoother by week two.

What if I'm at my goal weight on Saxenda?

This is the other scenario — you're on Saxenda, you hit your goal, and you're trying to decide whether to stay on it or move to something else. The answer is almost always: stay on something. All GLP-1s are maintenance drugs. Stopping leads to weight regain in most people — in the STEP-4 withdrawal trial, people who stopped semaglutide regained two-thirds of the weight they lost within a year. If Saxenda has gotten you to your target, the question is whether you'd prefer a once-weekly maintenance shot instead of a daily one. Most people, given the choice, switch to a weekly.

Compare Saxenda FAQs

Every drug on this page has its fans, its critics, and its clinical niche. Saxenda was a pioneer — it proved GLP-1s could deliver meaningful, durable weight loss. But "pioneer" and "best available in 2026" are not the same thing. If you're trying to decide what to put in your injection pen for the next year of your life, we hope this page has given you the honest numbers and honest trade-offs.